SYBX

SEC source: 0000899243-21-011334 · doc4.xml · nonDerivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,317

F1 · shares: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date.

SEC source: 0000899243-21-011332 · doc4.xml · derivative · entry 2

Awad Antoine · CIK 0001820122 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2031-03-10

F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021, subject to the Reporting Person continuing to provide services to the Issuer as Chief Operating Officer through each such vesting date.

SEC source: 0000899243-21-011332 · doc4.xml · nonDerivative · entry 1

Awad Antoine · CIK 0001820122 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,000

F1 · shares: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Operating Officer through each such vesting date.

SEC source: 0000899243-21-005927 · doc4.xml · derivative · entry 1

Kelly-Croswell Lisa · CIK 0001845596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-02-09

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

SEC source: 0001104659-21-001076 · tm211802-1_4seq1.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,498

Underlying: Common Stock · 57,498 shares

Expires 2031-01-04

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and audit committee cash retainers of $85,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2021 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-033178 · doc4.xml · derivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-12-08

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

SEC source: 0000899243-20-020582 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,541

Underlying: Common Stock · 1,541 shares

Expires 2030-07-24

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan in lieu of the non-employee director nominating and governance committee chair cash retainer of $8,000. Such options vest in four equal quarterly installments provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-015647 · doc4.xml · derivative · entry 1

Burgess Michael F. · CIK 0001801745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-015648 · doc4.xml · derivative · entry 1

Shea Richard P · CIK 0001294354 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-015644 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-20-035035 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-015650 · doc4.xml · derivative · entry 1

Hurter Patricia N. · CIK 0001767191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-015649 · doc4.xml · derivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-015645 · doc4.xml · derivative · entry 1

Leschly Nick · CIK 0001578408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-20-008100 · doc4.xml · derivative · entry 2

Riese Richard J. · CIK 0001786692 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2030-03-10

F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 10, 2020, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date.

SEC source: 0000899243-20-008100 · doc4.xml · nonDerivative · entry 1

Riese Richard J. · CIK 0001786692 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,500

F1 · shares: The shares of restricted stock were granted on March 10, 2020 (the "Grant Date") and will vest in four equal annual installments on each anniversary of the Grant Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date.

SEC source: 0000899243-20-008099 · doc4.xml · derivative · entry 2

Brennan Aoife · CIK 0001714563 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,300

Underlying: Common Stock · 185,300 shares

Expires 2030-03-10

F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 10, 2020, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date.

SEC source: 0000899243-20-008099 · doc4.xml · nonDerivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,067

F1 · shares: The shares of restricted stock were granted on March 10, 2020 (the "Grant Date") and will vest in four equal annual installments on each anniversary of the Grant Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date.

SEC source: 0000899243-20-002806 · doc4.xml · derivative · entry 1

Burgess Michael F. · CIK 0001801745 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

SEC source: 0000899243-20-020581 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,656

Underlying: Common Stock · 48,656 shares

Expires 2030-01-02

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and audit committee cash retainers of $77,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2020 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-000021 · doc4.xml · derivative · entry 1

Riese Richard J. · CIK 0001786692 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-12-31

F1 · derivative.exercise_date: The option will vest and become exercisable as to one-fourth (1/4) of the shares on September 16, 2020, and the remainder will vest and become exercisable at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as Chief Medical Officer through each such vesting date.

SEC source: 0000899243-19-029298 · doc4.xml · nonDerivative · entry 1

Shea Richard P · CIK 0001294354 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

SEC source: 0000899243-19-025927 · doc4.xml · derivative · entry 1

BELOFF GREGG · CIK 0001171002 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-10-23

F1 · derivative.exercise_date: The option vest with respect to 25% of the shares on a date that is 6 months from the date of grant, with the remaining shares to vest in equal monthly installments over the following 18 months, subject to the Reporting Person continuing to provide services to the Issuer as Interim Chief Financial Officer through each such vesting date.

SEC source: 0000899243-19-024251 · doc4.xml · nonDerivative · entry 1

PLEVY SCOTT ERIC · CIK 0001772683 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · shares: On September 23, 2019 (the "Grant Date"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date.

SEC source: 0000899243-19-024249 · doc4.xml · nonDerivative · entry 1

Riese Richard J. · CIK 0001786692 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · shares: On September 23, 2019 (the "Grant Date"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date.

SEC source: 0000899243-19-024248 · doc4.xml · nonDerivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,767

F1 · shares: On September 23, 2019 (the "Grant Date"), the reporting person was granted 8,000 shares of restricted stock of the company under the company's 2015 Equity Incentive Award Plan as part of a company-wide equity grant that was made to all employees. 100% of the shares of restricted stock will vest 18 months from the Grant Date.

SEC source: 0000899243-19-018631 · doc4.xml · derivative · entry 1

PLEVY SCOTT ERIC · CIK 0001772683 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-06-28

F1 · derivative.exercise_date: The option vested and became exercisable as to one-fourth (1/4) of the shares on May 6, 2019, and the remainder vest and become exercisable at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as Chief Scientific Officer through each such vesting date.

SEC source: 0000899243-19-015996 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-19-015994 · doc4.xml · derivative · entry 1

Shea Richard P · CIK 0001294354 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-19-015995 · doc4.xml · derivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0001209191-19-035601 · doc4.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-19-015998 · doc4.xml · derivative · entry 1

Leschly Nick · CIK 0001578408 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-19-015997 · doc4.xml · derivative · entry 1

Hurter Patricia N. · CIK 0001767191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-19-015993 · doc4.xml · derivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

SEC source: 0000899243-19-006432 · doc4.xml · derivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,000

Underlying: Common Stock · 185,000 shares

Expires 2029-03-05

F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on April 5, 2019 and continuing until March 5, 2023, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

SEC source: 0000899243-19-006431 · doc4.xml · derivative · entry 1

Shegog Todd · CIK 0001714564 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,500

Underlying: Common Stock · 58,500 shares

Expires 2029-03-05

F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments beginning on April 5, 2019 and continuing until March 5, 2023, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

SEC source: 0000899243-19-003603 · doc4.xml · nonDerivative · entry 2

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0000899243-19-003603 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,984

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0000899243-19-003342 · doc4.xml · derivative · entry 1

Hurter Patricia N. · CIK 0001767191 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-02-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

SEC source: 0000899243-19-010393 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,380

Underlying: Common Stock · 17,380 shares

Expires 2029-01-02

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $76,250 in the aggregate. Such options vest in four quarterly installments on the last day of each calendar quarter during 2019 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-18-027889 · doc4.xml · derivative · entry 1

Brennan Aoife · CIK 0001714563 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-10-31

F1 · derivative.exercise_date: The option vests and becomes exercisable as to one-fourth (1/4) of the shares on October 2, 2019, and the remainder will vest at one-forty-eighth (1/48th) of the shares per month thereafter, subject to the Reporting Person continuing to provide services to the Issuer as President and Chief Executive Officer through each such vesting date.

SEC source: 0000899243-18-027071 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to 9.80, inclusive.

SEC source: 0000899243-18-024753 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.96 to 13.14, inclusive.

SEC source: 0000899243-18-023995 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.78, inclusive.

SEC source: 0000899243-18-023638 · doc4.xml · nonDerivative · entry 2

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.77, inclusive.

SEC source: 0000899243-18-023638 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,477

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.80, inclusive.

SEC source: 0000899243-18-020190 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.05, inclusive.

SEC source: 0000899243-18-017588 · doc4.xml · nonDerivative · entry 3

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0000899243-18-017588 · doc4.xml · nonDerivative · entry 2

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.

SEC source: 0000899243-18-017588 · doc4.xml · nonDerivative · entry 1

Miller Paul Francis · CIK 0001714565 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,189

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2018.